ImmunityBio (IBRX) Return on Capital Employed (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Return on Capital Employed data on file, last reported at 51.63% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 51.63%, up 5493.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 51.63% (up 5493.0% YoY), and the FY2025 annual result was 67.26%, up 2128.0% from the prior year.
• Return on Capital Employed grew to 51.63% in Q1 2026 per IBRX's latest filing, from 57.06% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 1489.88% in Q2 2022 and troughed at 704.86% in Q1 2022.
• A 5-year average of 11.95% and a median of 88.32% in 2023 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed jumped 166516 bps in 2022, then sank 136413 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 245.3% in 2022, then plunged by 136 bps to 88.32% in 2023, then fell by 22 bps to 107.96% in 2024, then jumped by 47 bps to 57.06% in 2025, then grew by 10 bps to 51.63% in 2026.
• Business Quant data shows IBRX's Return on Capital Employed at 51.63% in Q1 2026, 57.06% in Q4 2025, and 64.64% in Q3 2025.